Valiant Laboratories Limited
NSE: VALIANTLAB BSE: VALIANTLAB
NSE
83.34
1.86 (2.28%)
Prev Close
81.48
Open Price
83.12
Volume
13,320
Today Low / High
81.79 / 83.6
52 WK Low / High
75.2 / 130.2
Range
79 - 88
BSE
83.63
1.14 (1.38%)
Prev Close
82.49
Open Price
82.76
Volume
451
Today Low / High
82.19 / 83.79
52 WK Low / High
75.86 / 136.8
Range
79 - 88
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 83.34 (target range: 79 - 88), reflecting a change of 1.86 (2.28277%). On the BSE, it is listed at 83.63 (target range: 79 - 88), showing a change of 1.14 (1.38199%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
01 Oct
83.12
0.26%
30 Sep
81.92
-0.54%
29 Sep
83.16
-1.55%
26 Sep
86.06
-4.09%
25 Sep
88.30
-3.33%
24 Sep
88.90
-0.67%
23 Sep
89.00
-1.08%
22 Sep
88.64
0.32%
19 Sep
87.31
-0.05%
18 Sep
87.75
-0.85%
17 Sep
87.85
-2.37%
16 Sep
87.87
-2.17%
15 Sep
86.78
0.32%
12 Sep
88.44
-1.88%
11 Sep
83.90
2.59%
10 Sep
84.32
-0.53%
09 Sep
84.99
-0.79%
08 Sep
85.15
-1.24%
05 Sep
86.00
-2.72%
04 Sep
88.89
-3.25%
Valiant Laboratories Limited Graph
Valiant Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Valiant Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 83.34, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 83.63 | 84.47 | 76.02 - 92.91 |
| 85.30 | 68.24 - 102.36 | ||
| 86.14 | 60.30 - 111.98 | ||
| Bearish Scenario | 83.63 | 82.79 | 74.51 - 91.07 |
| 81.96 | 65.57 - 98.35 | ||
| 81.12 | 56.78 - 105.46 |
Overview of Valiant Laboratories Limited
ISIN
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
92,274
Market Cap
3,621,203,673
Last Dividend
0
Official Website
IPO Date
2023-10-06
DCF Diff
225.22
DCF
-112
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 138.82 Cr | 116.60 Cr | 22.22 Cr | 0.1600 | 0.00 Cr | 0.00 Cr | 17.83 Cr | -2.20 Cr | -0.51 | 0.76 Cr | -0.0159 |
| 2024-03-31 | 182.06 Cr | 168.25 Cr | 11.58 Cr | 0.0636 | 0.00 Cr | 0.00 Cr | 7.26 Cr | 0.32 Cr | 0.08 | -8.60 Cr | 0.0018 |
| 2023-03-31 | 333.91 Cr | 277.32 Cr | 56.59 Cr | 0.1695 | 0.00 Cr | 0.65 Cr | 50.37 Cr | 29.00 Cr | 6.67 | 39.95 Cr | 0.0868 |
| 2022-03-31 | 291.52 Cr | 239.20 Cr | 52.32 Cr | 0.1795 | 0.00 Cr | 0.48 Cr | 40.01 Cr | 27.50 Cr | 6.33 | 44.27 Cr | 0.0943 |
| 2021-03-31 | 182.37 Cr | 123.98 Cr | 58.39 Cr | 0.3202 | 0.00 Cr | 0.56 Cr | 47.40 Cr | 30.59 Cr | 7.04 | 51.41 Cr | 0.1678 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.92 Cr | 400.86 Cr | 166.55 Cr | 234.3101 Cr | 121.69 Cr | 45.70 Cr | 3.99 Cr | 204.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 59.6157 Cr |
| 2024-03-31 | 11.72 Cr | 342.69 Cr | 105.83 Cr | 236.8612 Cr | 76.71 Cr | 64.99 Cr | 10.02 Cr | 92.70 Cr | 0.00 Cr | 0.00 Cr | -128.67 Cr | 29.0769 Cr |
| 2023-03-31 | 1.26 Cr | 212.97 Cr | 112.48 Cr | 100.4910 Cr | 60.22 Cr | 58.96 Cr | 13.04 Cr | 48.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 50.7260 Cr |
| 2022-03-31 | 0.13 Cr | 181.81 Cr | 110.35 Cr | 71.4600 Cr | 61.13 Cr | 61.00 Cr | 15.80 Cr | 23.67 Cr | 0.00 Cr | 0.00 Cr | 0.40 Cr | 49.4270 Cr |
| 2021-03-31 | 3.94 Cr | 106.31 Cr | 17.73 Cr | 88.5820 Cr | 0.60 Cr | -3.33 Cr | 6.07 Cr | 19.79 Cr | 0.00 Cr | 0.96 Cr | 0.00 Cr | 15.8870 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.3133 Cr | -52.7677 Cr | 44.6528 Cr | -112.5403 Cr | -6.8017 Cr | 4.9165 Cr | -113.8536 Cr | -2.2012 Cr | 29.6858 Cr | 0.0000 Cr | 6.0267 Cr |
| 2024-03-31 | 1.8854 Cr | -143.8768 Cr | 152.4479 Cr | -43.9849 Cr | 10.4566 Cr | 11.7182 Cr | -45.8703 Cr | -0.7695 Cr | 16.6503 Cr | 0.0000 Cr | 3.0270 Cr |
| 2023-03-31 | 56.0511 Cr | -55.1682 Cr | -0.9339 Cr | 18.3702 Cr | -0.0510 Cr | 1.2616 Cr | -37.6809 Cr | 28.9983 Cr | -1.2807 Cr | 0.0000 Cr | 2.7615 Cr |
| 2022-03-31 | 2.2510 Cr | -12.2380 Cr | 6.1810 Cr | -4.6250 Cr | -3.8060 Cr | 0.1310 Cr | -6.8760 Cr | 41.7040 Cr | -42.0720 Cr | 0.0000 Cr | -9.7310 Cr |
| 2021-03-31 | 9.1090 Cr | -16.6690 Cr | 11.4300 Cr | 7.4400 Cr | 3.8690 Cr | 3.9370 Cr | -1.6690 Cr | 47.0230 Cr | 13.2140 Cr | 0.0000 Cr | -2.2040 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 46.82 Cr | 39.72 Cr | 7.10 Cr | 0.1516 | 1.87 Cr | 1.82 Cr | 0.39 | 3.05 Cr | 0.0389 |
| 2025-03-31 | 55.47 Cr | 48.23 Cr | 7.25 Cr | 0.1306 | 6.12 Cr | 0.70 Cr | 0.16 | 3.09 Cr | 0.0127 |
| 2024-12-31 | 35.23 Cr | 28.72 Cr | 6.51 Cr | 0.1848 | 0.10 Cr | 2.35 Cr | 0.54 | 2.20 Cr | 0.0666 |
| 2024-09-30 | 21.48 Cr | 20.59 Cr | 0.89 Cr | 0.0413 | -7.26 Cr | -4.74 Cr | -1.09 | -3.38 Cr | -0.2207 |
| 2024-06-30 | 18.88 Cr | 19.00 Cr | -0.12 Cr | -0.0062 | -2.92 Cr | -0.51 Cr | -0.12 | -1.15 Cr | -0.0270 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 75.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -234.31 Cr |
| 2025-03-31 | 4.92 Cr | 71.07 Cr | 75.99 Cr | 72.12 Cr | 3.99 Cr | 192.62 Cr | 204.11 Cr | 400.86 Cr | 166.55 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 118.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -231.61 Cr |
| 2024-09-30 | 2.40 Cr | 116.58 Cr | 118.98 Cr | 0.03 Cr | 5.16 Cr | 191.36 Cr | 162.49 Cr | 360.96 Cr | 129.35 Cr |
| 2024-06-30 | -143.82 Cr | 287.65 Cr | 143.82 Cr | 0.00 Cr | 0.00 Cr | 143.82 Cr | 0.00 Cr | 0.00 Cr | -236.86 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.70 Cr | 1.31 Cr | -52.77 Cr | 44.65 Cr | 4.92 Cr | 4.92 Cr | 0.00 Cr | -113.85 Cr | -112.54 Cr |
| 2024-12-31 | 2.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -4.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,636.20 | ₹3,925,785,949,961.00 | ₹3,109,028.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,710.00 | ₹1,515,830,342,520.00 | ₹721,664.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,565.40 | ₹1,206,691,803,000.00 | ₹300,672.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,244.70 | ₹1,036,053,739,575.00 | ₹4,082,857.00 |
| Mankind Pharma Limited | MANKIND | ₹2,440.00 | ₹1,007,130,715,600.00 | ₹218,700.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹994.00 | ₹1,000,192,183,634.00 | ₹560,964.00 |
| Lupin Limited | LUPIN | ₹1,981.30 | ₹904,968,681,500.00 | ₹2,121,417.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,459.50 | ₹652,765,117,500.00 | ₹177,737.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,086.00 | ₹630,750,562,578.00 | ₹1,043,306.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,959.20 | ₹552,887,824,993.00 | ₹524,801.00 |
| Laurus Labs Limited | LAURUSLABS | ₹872.00 | ₹470,727,311,928.00 | ₹2,073,317.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,327.30 | ₹336,741,608,551.00 | ₹253,514.00 |
| Cohance Lifesciences Limited | COHANCE | ₹870.50 | ₹333,024,695,370.00 | ₹176,686.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,398.20 | ₹299,620,613,477.00 | ₹59,582.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,689.70 | ₹264,600,665,038.00 | ₹140,607.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,492.80 | ₹242,557,310,933.00 | ₹804,577.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,222.00 | ₹230,550,000,000.00 | ₹17,995.00 |
| Eris Lifesciences Limited | ERIS | ₹1,624.90 | ₹221,333,403,895.00 | ₹66,608.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,386.00 | ₹197,400,672,154.00 | ₹76,750.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹904.30 | ₹177,752,033,033.00 | ₹38,869.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,113.00 | ₹176,467,022,592.00 | ₹116,056.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,058.50 | ₹156,470,076,216.00 | ₹85,382.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹806.55 | ₹144,461,065,649.00 | ₹369,545.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹542.65 | ₹131,670,612,487.00 | ₹2,904,200.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,302.00 | ₹104,609,305,364.00 | ₹8,422.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹778.75 | ₹76,154,669,605.00 | ₹110,903.00 |
| Strides Pharma Science Limited | STAR | ₹819.15 | ₹75,503,278,673.00 | ₹223,057.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹829.10 | ₹75,143,794,598.00 | ₹230,230.00 |
| FDC Limited | FDC | ₹457.30 | ₹74,453,051,413.00 | ₹74,687.00 |
| Innova Captab Limited | INNOVACAP | ₹872.30 | ₹49,917,305,567.00 | ₹25,306.00 |
| Sequent Scientific Limited | SEQUENT | ₹194.90 | ₹48,708,014,270.00 | ₹626,582.00 |
| Suven Life Sciences Limited | SUVEN | ₹207.05 | ₹45,145,326,314.00 | ₹112,355.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹488.05 | ₹44,544,323,500.00 | ₹58,510.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹132.15 | ₹42,885,527,854.00 | ₹193,124.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,264.80 | ₹37,457,561,172.00 | ₹5,746.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹720.15 | ₹36,525,363,466.00 | ₹24,749.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹351.15 | ₹35,214,201,982.00 | ₹25,077.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹482.40 | ₹33,963,733,800.00 | ₹20,154.00 |
| Hikal Limited | HIKAL | ₹255.00 | ₹31,441,691,250.00 | ₹129,465.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹106.99 | ₹31,404,508,295.00 | ₹3,421,704.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.81 | ₹26,745,620,048.00 | ₹2,029,317.00 |
| Indoco Remedies Limited | INDOCO | ₹290.15 | ₹26,740,631,661.00 | ₹21,520.00 |
| Alembic Limited | ALEMBICLTD | ₹103.45 | ₹26,564,080,107.00 | ₹495,596.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹605.35 | ₹25,889,578,533.00 | ₹127,415.00 |
Key Executives
Chief Financial Officer & Executive Director
Mr. Paresh Shashikant Shah
Gender: male
Year Born: 1960
Head Accounts & Finance
Mr. Chandrakant Mahadeo Mandhare
Gender: male
Year Born: 1978
Head of R&D
Meghana Shivpal Wasnik
Gender: Not Specified
Year Born:
Research & Development Head
Mr. Nilesh Vinayak Patil
Gender: male
Year Born: 1983
Unit Head
Mr. Jyotibhushan Singh
Gender: male
Year Born: 1972
Company Secretary & Compliance Officer
Ms. Prajakta Kantishwar Patil
Gender: female
Year Born: 1992
Executive Officer
Ms. Rachi Santosh Vora
Gender: female
Year Born:
Managing Director & Executive Director
Mr. Santosh Shantilal Vora
Gender: male
Year Born: 1994
FAQs about Valiant Laboratories Limited
Who is the CEO of the company?
The CEO is Santosh Shantilal Vora.
What is the current market price of the stock?
The current price is ₹83.34.
What is the 52-week price range?
The range is ₹75.2-130.2.
What is the market capitalization of the company?
The market capitalization is ₹362.12 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 3,022.43.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Valiant Laboratories Limited (ISIN: ) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹362.12 crores and an average daily volume of 92,274 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.